Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVN461 in Non-infectious Anterior Uveitis
NCT07136805Phase 3Active, not recruiting
- Sponsor
- VivaVision Biotech
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of VVN461 (2 arms), sponsored by VivaVision Biotech. Primary endpoint: Change from baseline in anterior chamber cell (ACC) grade at 14 days. Started Nov 2025; status: active, not recruiting.
02
Drugs
VVN461
Beyond the preview
Go deeper on NCT07136805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136805.